VentriPoint Diagnostics (VPT) Stock Price, News & Analysis

Company Overview

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients. Ventripoint Diagnostics Ltd. is headquartered in Toronto, Canada.

Key Stats

• Today's Range: C$0.13 to C$0.14
• 50-Day Range: C$0.08 to C$0.19
• 52-Week Range: C$0.08 to C$0.30
• Volume: 153,500 shs
• Average Volume: 239,567 shs
• Market Capitalization: C$21.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VPT Stock Analysis - Frequently Asked Questions

How have VPT shares performed this year?

VentriPoint Diagnostics' stock was trading at C$0.10 on January 1st, 2025. Since then, VPT stock has increased by 35.0% and is now trading at C$0.14.
View the best growth stocks for 2025 here.

How do I buy shares of VentriPoint Diagnostics?

Shares of VPT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of VentriPoint Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VentriPoint Diagnostics investors own include Resverlogix (RVX), Meta Platforms (META), Sphere 3D (ANY), Aptose Biosciences (APTO), Antibe Therapeutics (ATE), AuRico Gold Inc. Ordinary Share (AUQ) and Baytex Energy (BTE).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: CVE:VPT
• CIK: N/A
• Web: www.ventripoint.com
• Phone: 416-848-4156
• Fax: N/A
• Employees: 147,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-5,250,009.92
• Net Margins: -3,732.10%
• Pretax Margin: N/A
• Return on Equity: 388.60%
• Return on Assets: -136.72%

Debt

• Debt-to-Equity Ratio: -58.56
• Current Ratio: 0.28
• Quick Ratio: 6.67

Sales & Book Value

• Annual Sales: C$140,671.91
• Price / Sales: 155.66
• Cash Flow: C$0.02 per share
• Price / Cash Flow: 5.53
• Book Value: C($0.02) per share
• Price / Book: -8.64

Miscellaneous

• Outstanding Shares: 162,204,000
• Free Float: N/A
• Market Cap: C$21.90 million
• Optionable: Not Optionable
• Beta: 0.39